Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic and locally recurrent breast cancer

Next Previous
X
Search
Trial Profile

A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line treatment for patients with HER2 negative metastatic and locally recurrent breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVADO
  • Sponsors Roche

    • Most Recent Events

    • 01 Jan 2013 New source identified and integrated (United Kingdom Clinical Research Network: 2607).
    • 18 Apr 2011 Planned End Date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 18 Sep 2010 The FDA has extended the review period, of results from this trial, for Genentech's supplemental Biologics Licence Application until 17 Dec 2010 according to a Genentech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top